Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 3, 2008, Pages 415-421

  Royer, Bernard ^a   Delroeux, Delphine ^a   Guardiola, Emmanuel ^a   Combe, Marielle ^a   Hoizey, Guillaume ^b   Montange, Damien ^a   Kantelip, Jean Pierre ^a   Chauffert, Bruno ^c   Heyd, Bruno ^a   Pivot, Xavier ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b HÔPITAL MAISON BLANCHE   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Cisplatin; Intraperitoneal Infusions; Ovarian neoplasms; Pharmacokinetic

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONFIDENCE INTERVAL; FEASIBILITY STUDY; HUMAN; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT SATISFACTION; PEROPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; INFUSIONS, PARENTERAL; INTRAOPERATIVE PERIOD; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN BINDING;

EID: 37249041054     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0484-x     Document Type: Article

References (23)

1. Ahmad SA, Kim J, Sussman JJ, Soldano DA, Pennington LJ, James LE, Lowy AM (2004) Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 11:387-392
2. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955
3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43
4. Bookman MA (2005) Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer 15(Suppl 3):212-220
5. Chatelut E, de Forni M, Canal P, Chevreau C, Roche H, Plusquellec Y, Johnson NP, Houin G, Bugat R (1991) Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies. Ann Oncol 2:217-221
6. Chauffert B, Favoulet P, Polycarpe E, Duvillard C, Beltramo JL, Bichat F, Rat P, Genne P, Benoit L (2003) Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives. Surg Oncol Clin N Am 12:835-848
7. Chauffert B, Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, Royer B, Monin-Baroille P, Flesch M, Fargeot M, Coudert B, Mayer F, Fumoleau P (2006) Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anticancer Drugs 10:1211-1217
8. Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, Figg WD (1999) Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 39:394-401
9. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8):viii7-viii12
10. Goodman MT, Howe HL (2003) Descriptive epidemiology of ovarian cancer in the United States, 1992-1997. Cancer 97:2615-2630
11. Goodman MT, Howe HL, Tung KH, Hotes J, Miller BA, Coughlin SS, Chen VW (2003) Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997. Cancer 97:2676-2685
12. Jaaback K, Johnson N (2006) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 1:CD005340
13. Kern W, Braess J, Kotschofsky M, Samel S, Becker H, Hiddemann W, Schleyer E (2002) Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity. Anticancer Res 22:3099-3102
14. Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4:277-283
15. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol 19:1001-1007
16. Markman M, Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24:988-994
17. Pignata S, Pisano C, Di Maio M, Iodice F, Casella G, Laurelli G, Greggi S, Iaffaioli RV (2006) Medical treatment of resistant or recurrent epithelial ovarian cancer. Ann Oncol 17(Suppl 7):vii49-vii50
18. Quinn M, Avall-Lundqvist E, du Bois A, Vermorken J, Parmar M, Pfisterer J, Stuart G, Thigpen T, Neijt J (2005) History, scope and methodology of the 3rd international consensus workshop on ovarian cancer 2004. Ann Oncol 16(Suppl 8):viii5-viii6
19. Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, Chaigneau L, Samain E, Chauffert B, Heyd B, Kantelip JP, Pivot X (2005) Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anticancer Drugs 16:1009-1016
20. Stuart GC (2003) First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 90:S8-S15
21. van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC (1998) Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34:148-154
22. van Ruth S, Verwaal VJ, Zoetmulder FA (2003) Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 12:771-780
23. Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FA (2001) Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 27:365-374